Management
Adam Rogers, MD
Chair, Interim Chief Executive Officer
Dr. Adam Rogers was the Interim President of NervGen Pharma Corp. from September 2022 to April 2023 and is a Principal of Boston-based PFP Biosciences Holdings and is a board-certified ophthalmologist specializing in diseases and surgery of the retina and vitreous. Dr. Rogers co-founded Hemera Biosciences in 2010, a clinical stage gene therapy biotech company targeting dry age-related macular degeneration. He assumed the role of CEO in 2017 and oversaw all aspects of the company until the Hemera assets were acquired in December 2020 by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson.
From 2001 to 2020 he served as an Assistant Professor of Ophthalmology at the New England Eye Center of Tufts Medical Center (Boston, MA). Dr. Rogers has published 29 articles in peer reviewed journals and co-authored two textbooks and numerous chapters in major ophthalmic textbooks. Since 2007 he has served on the board of One Family Inc., an organization whose mission is to end homelessness in Massachusetts. He is a member of the Emory University Board of Trustees. Dr. Rogers has a MD from Emory College and Emory School of Medicine.
Randall Kaye, MD
Chief Medical Advisor
Dr. Randall Kaye is the former Chief Medical Officer of Longboard Pharmaceuticals in San Diego, California where he oversaw the $2.6 billion acquisition of Longboard by Lundbeck A/S. Prior to Longboard, Dr. Kaye served as Chief Medical Officer at Neurana Pharmaceuticals, Click Therapeutics, Axsome Therapeutics and Avanir Pharmaceuticals. Earlier in his career, Dr. Kaye held leadership positions at Scios Inc., InterMune and Pfizer Inc. Dr. Kaye earned an MD, MPH and BS at George Washington University and was a Research Fellow at Harvard Medical School.
Bill Adams
Chief Financial Officer
Bill Adams, CPA, has over 30 years of strategic financial management experience that includes mergers and acquisitions, operations and capital markets in both Canada and the U.S., as well as corporate and operational finance having held a number of executive positions with high-growth technology and life sciences companies, including Chief Financial Officer roles at Anandia Laboratories Inc., Response Biomedical Corp., CellFor Inc., and AnorMED Inc.
He had a leading role in the sale of AnorMED to Genzyme for $580 million and was instrumental in the sale of Anandia in 2018 for $118 million. Mr. Adams has been responsible for completing over $250 million in public and private equity financing, including listing on the TSX and Nasdaq, and over $750 million in mergers and acquisitions and technology licensing transactions. Mr. Adams is a Chartered Professional Accountant, CA and holds a Bachelor of Commerce from the University of British Columbia.